DB
Danielle Brill Truist Securities Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Disc Medicine
IRON
$2.09B
| $60.19 | $86 |
43%
upside
| Buy | 1 month ago |
|
2
Alnylam Pharmaceuticals
ALNY
$59.4B
| $453.54 | $385 |
15%
downside
| Buy | 1 month ago |
|
3
Harmony Biosciences
HRMY
$2.09B
| $36.30 | $48 |
32%
upside
| Buy | 1 month ago |
|
|
PVLA
4
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $54.14 | $56 |
3%
upside
| Buy | 1 month ago |
|
|
TECX
5
Tectonic Therapeutic, Inc. Common Stock
TECX
$323M
| $17.27 | $64 |
271%
upside
| Buy | 1 month ago |
|
6
Neurocrine Biosciences
NBIX
$13.9B
| $140.40 | $163 |
16%
upside
| Buy | 1 month ago |
|
7
BridgeBio Pharma
BBIO
$9.91B
| $51.83 | $66 |
27%
upside
| Buy | 1 month ago |
|
|
CNTA
8
Centessa Pharmaceuticals
CNTA
$2.12B
| $15.79 | $30 |
90%
upside
| Buy | 1 month ago |
|
|
JCAP
9
Jefferson Capital, Inc. Common Stock
JCAP
$1.21B
| $18.64 | $24 |
29%
upside
| Buy | 1 month ago |
|
10
uniQure
QURE
$973M
| $17.73 | $52 |
193%
upside
| Strong Buy | 8 months ago |
|
|
TECX
11
Tectonic Therapeutic, Inc. Common Stock
TECX
$323M
| $17.27 | $65 |
276%
upside
| Outperform | 9 months ago |
|
12
BioMarin Pharmaceuticals
BMRN
$10.9B
| $56.75 | $79 |
39%
upside
| Outperform | 10 months ago |
|
13
Regenxbio
RGNX
$476M
| $9.42 | $18 |
91%
upside
| Outperform | 10 months ago |
|
|
14
Neurocrine Biosciences
NBIX
$13.9B
| $140.40 | $155 |
10%
upside
| Outperform | 10 months ago |
|
15
Immunovant
IMVT
$2.81B
| $16.12 | $36 |
123%
upside
| Outperform | 10 months ago |
|
|
16
Harmony Biosciences
HRMY
$2.09B
| $36.30 | $40 |
10%
upside
| Outperform | 10 months ago |
|
17
Sarepta Therapeutics
SRPT
$1.93B
| $18.46 | $150 |
713%
upside
| Outperform | 10 months ago |
|
18
argenx
ARGX
$44.9B
| $733.66 | $605 |
18%
downside
| Strong Buy | 10 months ago |
|
19
Xenon Pharmaceuticals
XENE
$2.98B
| $38.64 | $50 |
29%
upside
| Outperform | 10 months ago |
|
20
Agios Pharmaceuticals
AGIO
$2.1B
| $36.13 | $51 |
41%
upside
| Outperform | 10 months ago |
|
|
21
Disc Medicine
IRON
$2.09B
| $60.19 | $43 |
29%
downside
| Outperform | 1 year ago |
|